Overview

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Status:
Recruiting
Trial end date:
2025-09-05
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation